| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - AACAP: Deprenyl May Result In AD/HD Symptom Improvements By Lara Pullen Special to DG News CHICAGO, IL -- October 26, 1999 -- Some children do not respond to the stimulant medication that is frequently prescribed for attention deficit/hyperactivity disorder (AD/HD). Deprenyl (a monamine oxidase inhibitor - type B drug) is traditionally prescribed for the treatment of Parkinson’s Disease, but a new study suggests that it may be able to help these AD/HD children.
Dr. Molly A. Malone, of The Hospital for Sick Children, in Toronto, presented the results of a double-blind, placebo-controlled pilot project at the 46th annual meeting of the American Academy of Child and Adolescent Psychiatry. The results of this study built upon previous findings from a non-controlled study that demonstrated the benefits of deprenyl in children diagnosed with AD/HD. Ten children (ages six to 13) with AD/HD participated in the study. These children had very severe AD/HD and presented many co-morbid problems. Placebo and deprenyl tablets (5 mg) were given twice a day for one month each. Results showed that three tasks were significantly improved (paired-associate learning, math computation and Beery shape copying) with deprenyl treatment as determined by a two-tailed statistical test. This pilot study indicates that deprenyl may have some benefits for the task performance and classroom behavior of some children with AD/HD.
|